Incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): An updated systematic review of population-based reports from 2010 to 2023

被引:0
|
作者
Nordstrand, Magnus Andreas [1 ]
Lea, Dordi [2 ]
Soreide, Jon Arne [1 ,3 ]
机构
[1] Stavanger Univ Hosp, Dept Gastrointestinal Surg, N-4068 Stavanger, Norway
[2] Stavanger Univ Hosp, Dept Pathol, Stavanger, Norway
[3] Univ Bergen, Dept Clin Med, Bergen, Norway
关键词
gastroenteropancreatic neuroendocrine neoplasms; GEP-NENs; incidence; neuroendocrine neoplasms; population-based; TUMORS; SURVIVAL; EPIDEMIOLOGY; NETHERLANDS; IMMUNOHISTOCHEMISTRY; SYNAPTOPHYSIN; OUTCOMES;
D O I
10.1111/jne.70001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a general perception that the incidence of neuroendocrine neoplasms (NENs) has been increasing. Nevertheless, reports of actual population-based studies are scarce, and pertinent data from some geographical regions still need to be available. In this systematic literature review of population-based studies, we aimed to evaluate the available data to provide updated figures on the incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Guided by the PRISMA 2020 statement reporting items for systematic reviews, this study conducted a systematic search using Ovid in the bibliographic databases Embase, Medline, and Web of Science Core Collection. Only incidence-reporting studies were included. In total, 847 articles were identified, and through a strict evaluation process using predefined inclusion and exclusion criteria, we found 19 papers that reported the general incidence of GEP-NENs from all sites. In addition, we considered another 15 papers that focused on the epidemiologic aspects of single-organ studies. While the incidence rates of GEP-NEN vary across similar countries, the general incidence of GEP-NEN has been increasing worldwide in recent decades. The incidence of GEP-NENs has increased worldwide over the last two decades, and reliable figures from new regions add to this pattern. Nevertheless, variations in the classification, grading, and reporting of GEP-NENs in various studies make direct comparisons difficult.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update
    Christo Kole
    Nikolaos Charalampakis
    Michail Vailas
    Maria Tolia
    Maria Sotiropoulou
    Sergios Tsakatikas
    Nikolaos-Iasonas Kouris
    Marina Tsoli
    Anna Koumarianou
    Michalis V. Karamouzis
    Dimitrios Schizas
    Cancer Immunology, Immunotherapy, 2022, 71 : 761 - 768
  • [2] Role of Bispecific Antibodies in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Review of Literature
    Mohamed, Amr
    Elhawi, Mai
    Trybula, Marcus
    Elshawy, Mohamed
    Chakrabarti, Sakti
    Selfridge, Eva
    Asa, Sylvia L.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024, 18
  • [3] Autophagy flux is induced in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
    Angelioudaki, I.
    Theochari, M.
    Koniaris, E.
    Kataki, A.
    Stoupis, L.
    Mitrousias, A.
    Tzingounis, A-G.
    Dafnios, N.
    Zografos, G.
    Kafiri, G.
    Konstadoulakis, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S956 - S957
  • [4] Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Puccini, Alberto
    Poorman, Kelsey
    Salem, Mohamed E.
    Soldato, Davide
    Seeber, Andreas
    Goldberg, Richard M.
    Shields, Anthony F.
    Xiu, Joanne
    Battaglin, Francesca
    Berger, Martin D.
    Tokunaga, Ryuma
    Naseem, Madiha
    Barzi, Afsaneh
    Iqbal, Syma
    Zhang, Wu
    Soni, Shivani
    Hwang, Jimmy J.
    Philip, Philip A.
    Sciallero, Stefania
    Korn, W. Michael
    Marshall, John L.
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5943 - 5951
  • [5] Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update
    Kole, Christo
    Charalampakis, Nikolaos
    Vailas, Michail
    Tolia, Maria
    Sotiropoulou, Maria
    Tsakatikas, Sergios
    Kouris, Nikolaos-Iasonas
    Tsoli, Marina
    Koumarianou, Anna
    Karamouzis, Michalis V.
    Schizas, Dimitrios
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (04) : 761 - 768
  • [6] Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature
    Abdel-Rahman, Omar
    Fouad, Mona
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (02) : 295 - 305
  • [7] Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature
    Omar Abdel-Rahman
    Mona Fouad
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 295 - 305
  • [8] Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Alexandraki, Krystallenia I.
    Daskalakis, Kosmas
    Tsoli, Marina
    Grossman, Ashley B.
    Kaltsas, Gregory A.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2020, 31 (03): : 239 - 255
  • [9] Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Kaliszewski, Krzysztof
    Ludwig, Maksymilian
    Greniuk, Maria
    Mikula, Agnieszka
    Zagorski, Karol
    Rudnicki, Jerzy
    CANCERS, 2022, 14 (08)
  • [10] Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione, Massimo
    ENDOCRINE, 2018, 59 (01) : 1 - 3